StockMarketWire.com - Shire has revealed a positive outcome from the European Decentralised Procedure for Elvanse, which will be known as Tyvense in Ireland.
Elvanse is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) acted as the reference member state on behalf of seven other European countries participating in the procedure (Denmark, Finland, Germany, Ireland, Norway, Spain and Sweden).
At 2:07pm: [LON:SHP] Shire Pharmaceuticals Group share price was +6.5p at 1929.5p
Story provided by StockMarketWire.com
MoneyAM.com
MoneyAM website is aimed at investors of all levels of experience including City professionals, investors and full-time traders.
- Free live share prices
- Free live watch lists
- UK and Worldwide Indices
- Live market News
- Company Fundamentals
- Charts - Intraday and historic
- Stock Portfolio
Shares Magazine
Shares is the leading weekly publication for high net worth private investors and stock market professionals and as such is read weekly by thousands of private investors, analysts, fund managers, stockbrokers and company directors.
Broker Forecasts
Brokerforecasts.com publishes equity upgrades, downgrades, reiterations, resumption and drops in coverage, as well as price target changes to a desktop or via alerts to email.
All recommendations are delivered and updated as soon as possible after release. The majority will be on brokerforecasts.com prior to market open.
Directors Holdings
Company directors know the state of their business better than anyone. That's why professional investors like to keep a close watch on the directors who are buying and selling and often follow their lead. DirectorsHoldings.com provides all the necessary screening and search tools.